Back to search

Article

Concurrent Chemoradiation in Locally Advanced Lung Cancer with Cisplatin–Etoposide or Carboplatin–Paclitaxel: An Institutional Analysis

2026-04-22

Abstract excerpt

Concurrent chemoradiation (cCRT) is standard for unresectable, locally advanced non–small cell lung cancer (NSCLC), but the preferred concurrent chemotherapy backbone is uncertain. Cisplatin–etoposide (EP) and weekly carboplatin–paclitaxel (PC) are commonly used. Background/Objectives: Retrospective single-institution cohort of adults with histologically confirmed, inoperable AJCC stage II–III NSCLC treated 2015–2...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
df35eb6f-7f5b-5c04-842d-a236df0ea9e1
DOI
10.20944/preprints202604.1586.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Concurrent Chemoradiation in Locally Advanced Lung Cancer with Cisplatin–Etoposide or Carboplatin–Paclitaxel: An Institutional AnalysisDOI 10.20944/preprints202604.1586.v1
Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity
Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.Semantic proximity
Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial.Semantic proximity
Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.Semantic proximity
Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study.Semantic proximity
Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors.Semantic proximity
Thoracic radiotherapy synergizes with first-line EGFR-TKIs in advanced EGFR-mutant NSCLC: A dual-center real-world study.Semantic proximity
Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIsSemantic proximity
Comparative Safety of Immune Checkpoint Inhibitors and Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-AnalysisSemantic proximity
Comparison of efficacy and safety of first-line treatment options for unresectable stage III non-small cell lung cancer: a retrospective analysisSemantic proximity
Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial.Semantic proximity
Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Plus Thoracic Radiotherapy Improves Survival in Patients with Epidermal Growth Factor Receptor-Mutated Stage IV Non-Small Cell Lung CancerSemantic proximity
Select a neighboring publication to make it the new centre.